ExcepGen is a San Francisco, CA-based genetic medicine startup that emerged from stealth and is advancing nucleic acid therapeutics. The company encodes a specialized "shield" protein alongside main nucleic acid cargo to improve how cells react to foreign DNA or RNA and prevent negative cell signaling. This mechanism is intended to enhance the effectiveness and tolerability of DNA- and RNA-based genetic medicines, potentially expanding their reach. ExcepGen is led by CEO Thomas Folliard and Barbara Mertins. The company raised $4M in its latest funding round, bringing total capital raised to $14M. It plans to use the proceeds to accelerate research and development and to advance collaborations with other companies.

Total raised

$4M

Funding rounds

1

Latest round

Seed

Latest activity

Aug 2023